What is Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical is a rare disease biopharmaceutical company company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Rare disease biopharmaceutical company
- Headquarters
- Novato, United States
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: RARE
What is Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical is a rare disease biopharmaceutical company company headquartered in Novato, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Ultragenyx Pharmaceutical is a rare disease biopharmaceutical company company headquartered in Novato, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Ultragenyx Pharmaceutical should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Ultragenyx Pharmaceutical offer?
Ultragenyx Pharmaceutical's profile centers on Rare disease medicines, Gene therapy, Metabolic diseases, Clinical development.
- Rare disease medicines· Rare disease biopharmaceutical company
- Gene therapy· Rare disease biopharmaceutical company
- Metabolic diseases· Rare disease biopharmaceutical company
- Clinical development· Rare disease biopharmaceutical company
- Commercialization· Rare disease biopharmaceutical company
- R&D· Rare disease biopharmaceutical company
How does Ultragenyx Pharmaceutical make money?
Ultragenyx Pharmaceutical makes money through commercial activity tied to rare disease biopharmaceutical company.
Ultragenyx Pharmaceutical monetizes through the model common to rare disease biopharmaceutical company: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical's named executives should be verified on the official leadership or investor-relations page before outreach.
- Ultragenyx Pharmaceutical executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Ultragenyx Pharmaceutical finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Ultragenyx Pharmaceutical operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Ultragenyx Pharmaceutical's leadership?
Ultragenyx Pharmaceutical should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.ultragenyx.com- Ultragenyx Pharmaceutical investor relationsInvestor relations / corporate contactcontact via https://www.ultragenyx.com
- Ultragenyx Pharmaceutical sales or partnershipsCommercial contact routecontact via https://www.ultragenyx.com
- Ultragenyx Pharmaceutical media relationsMedia or communications contact routecontact via https://www.ultragenyx.com
How is Ultragenyx Pharmaceutical funded?
Ultragenyx Pharmaceutical's current status is Public company; Nasdaq: RARE.
Ultragenyx Pharmaceutical's capital profile is best understood through its current public-company status: Public company; Nasdaq: RARE. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Ultragenyx Pharmaceutical get here?
Ultragenyx Pharmaceutical's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingUltragenyx Pharmaceutical is foundedThe company begins building in rare disease biopharmaceutical company.
- Scale-upCommercial footprint expandsUltragenyx Pharmaceutical broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: RAREPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Ultragenyx Pharmaceutical's competitors?
Ultragenyx Pharmaceutical competes with larger incumbents and focused specialists in rare disease biopharmaceutical company.
Ultragenyx Pharmaceutical — frequently asked questions
